The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Open accessAbstract
Purpose: Given the molecular pathophysiology of thyroid cancer and the spectrum of kinases inhibited by sorafenib, including Raf kinase, vascular endothelial growth factor receptors, platelet-derived growth factor receptor, and RET tyrosine kinases, we conducted an open-label phase II trial to determine the efficacy of sorafenib in patients with advanced thyroid carcinoma. Patients and Methods: Eligible patients with metastatic, iodine-refractory thyroid carcinoma received sorafenib 400 mg orally twice daily. Responses were measured radiographically every 2 to 3 months. The study end points included response rate, progression-free survival (PFS), and best response by Response Evaluation Criteria in Solid Tumors. Results: Thirty patients were entered onto the study and treated for a minimum of 16 weeks. Seven patients (23%; 95% CI, 0.10 to 0.42) had a partial response lasting 18+ to 84 weeks. Sixteen patients (53%; 95% CI, 0.34 to 0.72) had stable disease lasting 14 to 89+ weeks. Seventeen (95%) of 19 patients for whom serial thyroglobulin levels were available showed a marked and rapid response in thyroglobulin levels with a mean decrease of 70%. The median PFS was 79 weeks. Toxicity was consistent with other sorafenib trials, although a single patient died of liver failure that was likely treatment related. Conclusion: Sorafenib has clinically relevant antitumor activity in patients with metastatic, iodine-refractory thyroid carcinoma, with an overall clinical benefit rate (partial response + stable disease) of 77%, median PFS of 79 weeks, and an overall acceptable safety profile. These results represent a significant advance over chemotherapy in both response rate and PFS and support further investigation of this agent in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Sherma, S. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12488-9 · Cited by 925
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Tuttle, R. M., Drucker, W., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 587
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Shimaoka, K., Schoenfeld, D. A., Dewys, W. D., Creech, R. H., & Deconti, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e · Cited by 464
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 405
RUEGEMER, J. J., HAY, I. D., BERGSTRALH, E. J., RYAN, J. J., OFFORD, K. P., & GORMAN, C. A. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-501 · Cited by 389
Shoup, M., Stojadinovic, A., Nissan, A., Ghossein, R. A., Freedman, S., Brennan, M. F., Shah, J. P., & Shaha, A. R. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00332-6 · Cited by 280
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Ciampi, R., & Nikiforov, Y. E. (2007) · Endocrinology · doi:10.1210/en.2006-0921 · Cited by 241
Chemotherapy of Thyroid Cancer with Adriamycin: Experience with 30 Patients
Gottlieb, J. A., & Hill, C. S. (1974) · New England Journal of Medicine · doi:10.1056/nejm197401242900404 · Cited by 235
Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population
Kim, K. H., Kang, D. W., Kim, S. H., Seong, I. O., & Kang, D. Y. (2004) · Yonsei Medical Journal · doi:10.3349/ymj.2004.45.5.818 · Cited by 229
Ratain, M. J., & Eckhardt, S. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.960 · Cited by 227
Murphy, D. A., Makonnen, S., Lassoued, W., Feldman, M. D., Carter, C., & Lee, W. M. F. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050711 · Cited by 154
Abdel‐Rahman, M. H., Yang, Y., Zhou, X.-P., Craig, E. L., Davidorf, F. H., & Eng, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2418 · Cited by 129
Tuttle, R. M., Fleisher, M., Francis, G. L., & Robbins, R. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8388 · Cited by 93
Wells, S. A., Gosnell, J. E., Gagel, R. F., Moley, J. F., Pfister, D. G., Sosa, J. A., Skinner, M., Krebs, A., Hou, J., & Schlumberger, M. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.6018 · Cited by 89
Madalinska, J. B., van Beurden, M., Bleiker, E. M. A., Valdimarsdottir, H. B., Lubsen-Brandsma, L. A. C., Massuger, L. F. A. G., Mourits, M. J. E., Gaarenstroom, K. N., van Dorst, E. B. L., van der Putten, H. W. H. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4922 · Cited by 77
Bauer, A. J., Terrell, R., Doniparthi, N. K., Patel, A. D., Tuttle, R. M., Saji, M., Ringel, M. D., & Francis, G. L. (2002) · Thyroid · doi:10.1089/105072502320908286 · Cited by 69
Kloos, R. T., Ringel, M. D., Knopp, M. V., Heverhagen, J. T., Rittenberry, J., Weldy, L., Arbogast, D., Collamore, M., King, M., Young, D. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5534 · Cited by 30
Sherman, S. I., Schlumberger, M. J., Droz, J., Hoffmann, M., Wirth, L. J., Bastholt, L., Martins, R. G., Licitra, L. F., Shi, Y., & Stepan, D. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.6017 · Cited by 20
Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma
Gupta, V., Puttaswamy, K., Lassoued, W., Redlinger, M., Ransone, K., Gold, K. A., Lee, W., LiVolsi, V. A., Fraker, D. L., Mandel, S. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.6019 · Cited by 17
Self-citation
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Self-citationBrose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Self-citationWells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Metadata
- Authors
- Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., & Brose, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-10
- Volume
- 26
- Issue
- 29
- Pages
- 4714-4719
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158801409
- Cited by
- 680
- References
- 31
- FWCI
- 49.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.